We still have 15k shares of VCEL with cost basis of $3.32. We surely are not down 96.2% from all time high; rather we are up 1066.85% at close of $38.75.
Assuming VCEL gets the NexoBrid approval this year, I can see your 1066.85% becoming 5000% by end 2023. Not kidding here, all VCEL products are basically without competition and without generic pathways.
What do you see re direction of market the rest of year, AMRN in particular?
I only have a small position in AMRN........ its prospects seem murky to me, they don't seem to have stemmed generic erosion in the USA, and its always the USA that gets reflected in price.... of course PFE signing on for Canadian sales suggests interest. As for the market, who knows, but one would think recovery to some norm is inevitable. The most clear winners like VCEL should lead.
Market Data 
Markets 
AI
